These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11148444)

  • 1. Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.
    Calleja JL; Albillos A; Rossi I; Moreno R; Domper F; Martínez JL; Escartín P
    Aliment Pharmacol Ther; 2001 Feb; 15(2):241-9. PubMed ID: 11148444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.
    Moreno-Monteagudo JA; Castro A; De Pedro A; Lorenzo JA; Fernández-Bermejo M; Lopez S; García-Buey L; Borque MJ; Pedreira JD; Moreno-Otero R
    Aliment Pharmacol Ther; 2002 Feb; 16(2):243-9. PubMed ID: 11860407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
    Mangi A; Villani MR; Minerva N; Leandro G; Bacca D; Cela M; Carretta V; Attino V; Ventrella F; Giangaspero A; Andriulli A
    J Hepatol; 2001 Mar; 34(3):441-6. PubMed ID: 11322207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
    Pár A; Roth E; Miseta A; Hegedüs G; Pár G; Hunyady B; Vincze A
    Orv Hetil; 2009 Jan; 150(2):73-9. PubMed ID: 19103558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
    Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Furione L; Idéo G
    J Hepatol; 2000 Sep; 33(3):463-8. PubMed ID: 11020003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
    Brouwer JT; Hansen BE; Niesters HG; Schalm SW
    J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
    Westin J; Lindh M; Nenonen N; Lagging LM; Norkrans G; Wejstål R
    Scand J Infect Dis; 2001; 33(2):110-5. PubMed ID: 11233844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
    Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
    Nyberg L; Albrecht J; Glue P; Gianelli G; Zambas D; Elliot M; Conrad A; McHutchison J
    J Clin Gastroenterol; 1999 Jun; 28(4):313-6. PubMed ID: 10372927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.